Real-Life Efficacy of Palbociclib and Ribociclib in Advanced Breast Cancer
<b>Background:</b> Clinical trials in metastatic hormone receptor-positive (HR+) human epidermal growth factor receptor-2 (HER2)-negative patients have shown that cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors both increase response rates and provide survival benefits. The efficacy of...
| Published in: | Current Oncology |
|---|---|
| Main Authors: | , , , |
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-03-01
|
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/32/3/161 |